Liberação de oxigênio em dentes bovinos clareados com peróxido de carbamida e sua influência na resistência de união ao cisalhamento e microinfiltração em restaurações adesivas

Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em Odontologia.Avaliou-se ,"in vitro", os efeitos do clareamento caseiro com peróxido de carbamida a 15% , na liberação de oxigênio, na resistência de união e na microinfiltração de restaurações diretas com resina composta. Para titulação os dentes foram divididos em 4 grupos e para cisalhamento associado a microinfiltração os dentes foram divididos em 2 grupos. De acordo com os resultados concluiu-se que: dentes clareados com peróxido de carbamida a 15% e após 6 h restaurados com resina composta e sistema adesivo, sofrem redução dos valores de resistência de união ao cisalhamento e aumentam o grau de microinfiltração; dentes clareados com peróxido de carbamida a 15% são capazes de liberar quantidades significativamente maiores de oxigênio

Effect of saliva contamination on cementation of orthodontic brackets using different adhesive systems

The enamel condition and the quality of surface are points that need to be considered for achieving optimal efficiency in the treatment with orthodontic brackets. The aim of this study was to assess the immediate bond strength of metallic brackets cemented to dental. Forty human premolars were double-sectioned, placed in PVC matrices and randomly divided into 10 groups (n=8). They received artificial saliva contamination before or after the application of adhesive systems, except for the control groups. The metallic brackets were cemented using two orthodontic cements (Transbond? Plus Color Change, 3M Unitek e Transbond? XT Light, 3M Unitek). The specimens were subjected to mechanical shear bond strength testing and classified according to the fracture pattern. The results were analyzed using a two-way ANOVA and Tukey?s test for multiple comparisons (p<0.05). ANOVA analysis showed statistically significant differences between the groups (p=0.01). The Tukey?s multiple comparison test indicated statistically significant difference between G6 and G7 groups (p<0.05). A high prevalence of adhesive failure in the groups receiving the hydrophobic adhesive system. The saliva contamination prior to the application of a hydrophobic simplified conventional adhesive system was responsible for decreasing the immediate bond strength values of brackets cemented on the dental enamel

Histometric analysis of alveolar bone regeneration with expanded polytetrafluoroethylene (e-PTFE) and latex membranes

AIM: To investigate the amount of connective tissue migrated into the extraction socket using EPTFE and latex membranes. METHODS: Seventeen rats were selected and randomly divided into 3 groups: e-PTFE membrane (n = 6), Latex membrane (n = 6) and Control (no membrane, n=5). After extraction of the maxillary right incisor, the animals of the test groups were subjected to alveolar guided bone regeneration (GBR) surgery and received an expanded polytetrafluoroethylene (e-PTFE) and a latex membrane, respectively. Thirty days after surgery, the animals were killed and histometric analysis was done to evaluate the migration of connective tissue. Data were analyzed statistically by one-way ANOVA and multiple-comparison Tukey's test at 5% significance level. RESULTS: There was statistically significant difference between groups e-PTFE and Latex (p=0.001), and between groups e-PTFE and Control (p=0.012), but no significant difference was found between groups Latex and Control (p=0.416). CONCLUSIONS: The e-PTFE membrane showed better results and appeared more adequate for GBR therapy, forming a barrier to prevent the migration of connective tissue into the extraction socket. The latex membrane, on the other hand, did not show benefits over the control group

Asymptotic Behavior of the Solution to a Nonisentropic Hydrodynamic Model of Semiconductors

AbstractWe study the asymptotic behavior of the solution for a hydrodynamic model of semiconductors where the energy equation is included. We study the case where the flow is subsonic and the doping profile is close to a negative constant, depending on the spacial variablex. We shall show that a given steady state solution is asymptotically stable or unstable depending on whether or not the density of the initial data satisfiesP=0, wherePis defined in (3.5)

PERSPECTIVA PSICOSOCIAL DE LOS DERECHOS HUMANOS

Hoy en día es imprescindible abordar el problema de los derechos desde una perspectiva holística que integre la posición que el individuo ocupa en la sociedad y el impacto de los hechos sociales sobre su persona. Esta perspectiva va por lo tanto más allá del enfoque clásico de las violaciones a los derechos civiles y políticos de los ciudadanos sino, también incluye sus derechos económicos, sociales y culturales. Cualquier enfoque de tipo holístico debe entender al ser humano en su ambiente, social, cultural, natural y en función a todas las estructuras existentes, por más sutiles que sean o invisibles que parezcan. Precisamente este libro permite apreciar la dimensión amplia y compleja del ser en sociedad y las interacciones que de ambas partes se generan y las ramificaciones que producen. No es un ejercicio fácil y los editores de este volumen han logrado un salto cuántico al poder congregar en un solo espacio miradas que en otras circunstancias podrían haber sido opuestas y hasta contrarias a nuestra comprensión de problemas que, en efecto, tienen raíces comunes. El libro está dividido en 5 secciones, El espíritu de los tiempos actuales y los Derechos Humanos, Construcción ciudadana y ejercicio de los Derechos Humanos, Violaciones a Derechos Humanos, victimizaciones y su atención, Ejercicio de los Derechos Humanos y situaciones disruptivas y Defensa y defensores de Derechos Humanos.Manuel Gutiérrez Romero Jessica Ruiz Magañ

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension